Literature DB >> 11911965

Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.

Ratnakar Patti1, Kiranmai Gumired, Pallu Reddanna, Leslie N Sutton, Peter C Phillips, C Damodar Reddy.   

Abstract

In this study the role of cyclooxygenase-2 (COX-2) in primitive neuroectodermal tumor (PNET) the most malignant brain tumors of childhood was investigated. COX-2 expression in human brain tumor biopsy samples (seven/seven) was about 6-8-fold higher than normal brain tissue and several PNET cell lines also express COX-2. The effect of selective COX-2 inhibitors, celecoxib and rofecoxib on the growth of two PNET cell lines (DAOY and PFSK) was determined. Celecoxib was more potent than rofecoxib in suppressing cell growth. Growth inhibition by celecoxib and rofecoxib was independent of Bcl-2 expression. Celecoxib suppressed the expression of Akt and activated the caspase-3 in DAOY and PFSK, whereas rofecoxib did not have such an effect.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11911965     DOI： 10.1016/s0304-3835(02)00003-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

Review 3.  Anti-angiogenic therapy in pediatric neuro-oncology.

Authors:  Mark W Kieran
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

4.  Efficacy of phenyl quinoline phenol derivatives as COX-2 inhibitors; an approach to emergent the small molecules as the anti-inflammatory and analgesic therapeutics.

Authors:  A Manikandan; S Ravichandran; K I Sathiyanarayanan; A Sivakumar
Journal:  Inflammopharmacology       Date:  2017-04-04       Impact factor: 4.473

Review 5.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

6.  Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors:  Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal:  BMJ       Date:  2002-09-21

Review 7.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

8.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031

9.  Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

Authors:  Brian R Budenholzer
Journal:  BMJ       Date:  2002-07-20

Review 10.  Is human cytomegalovirus a target in cancer therapy?

Authors:  John Inge Johnsen; Ninib Baryawno; Cecilia Söderberg-Nauclér
Journal:  Oncotarget       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.